| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| Type 1 Diabetes Extension Study | — | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic MiniMed, Inc. | <1 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | N/A | LifeNet Health | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | <1 mi |
| Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem | N/A | University of California, San Francisco | <1 mi |
| Automated Insulin for Management of Intrapartum Glycemia | N/A | University of California, San Francisco | <1 mi |
| Village-Integrated Eye Worker Trial II | N/A | University of California, San Francisco | <1 mi |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | <1 mi |
| Strategies for Improving Linkage-to-Care After Eye Disease Screening | N/A | University of California, San Francisco | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Precision Dosing of Metformin in Youth With T2D | Early 1 | University of California, San Francisco | <1 mi |
| AIDANET Pediatrics | N/A | Mark D. DeBoer, MD, MSc., MCR | <1 mi |
| Inflammation, Diabetes, Ethnicity and Obesity Cohort | — | University of California, San Francisco | <1 mi |
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | Phase 2 | Mannkind Corporation | <1 mi |
| Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management | N/A | Legacy Medical Consultants | <1 mi |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | <1 mi |
| Commercial or Open Source Closed Loop Impact on Pregnancy Study | — | University of California, San Francisco | <1 mi |
| A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States | — | Sanofi | <1 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | <1 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | <1 mi |
| Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center | N/A | University of California, San Francisco | <1 mi |
| DFC 004 Biomarkers for Active Diabetic Foot Ulcers | — | University of Michigan | <1 mi |
| Implementation of Team Clinic for Type 2 Diabetes (TCT2) | N/A | Children's Hospital Los Angeles | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| HLA Demographics Study in Adults With Type 1 Diabetes | — | GentiBio, Inc | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| Care Navigator Support for Younger Latinx Adults With Type 2 Diabetes | N/A | Kaiser Permanente | 8 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 13 mi |
| Safer Aging With Diabetes Monitoring | N/A | Kaiser Permanente | 15 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | 16 mi |
| A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. | N/A | Molnlycke Health Care AB | 19 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | 20 mi |
| Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM | N/A | i-SENS, Inc. | 21 mi |
| Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus | Phase 2 | Op-T LLC | 21 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Novo Nordisk A/S | 21 mi |
| ROME GS System Study | N/A | Senseonics, Inc. | 21 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | 21 mi |
| Dementia and Diabetes Prevention Program | N/A | University of California, Davis | 21 mi |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | 21 mi |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | 21 mi |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | Corxel Pharmaceuticals | 21 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 24 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | 25 mi |
| Addressing Diabetes by Elevating Access to Nutrition | N/A | Stanford University | 25 mi |
| Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Phase 4 | Stanford University | 28 mi |
| CHIME: Comparing Health Interventions for Maternal Equity | N/A | Stanford University | 28 mi |
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Phase 2 | Vantage Biosciences Ltd | 28 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | 28 mi |
| Food Insecurity Reduction & Strategy Team | N/A | Stanford University | 28 mi |
| Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes | Phase 1 | Stanford University | 28 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | 28 mi |
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation | Phase 2 | Qlaris Bio, Inc. | 28 mi |
| Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease | N/A | Duk-Woo Park, MD | 28 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 28 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 28 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | 28 mi |
| Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH) | N/A | Stanford University | 28 mi |
| BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes | N/A | Stanford University | 28 mi |
| SPYRAL GEMINI Pilot Study | N/A | Medtronic Vascular | 28 mi |
| Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes | N/A | Stanford University | 28 mi |
| Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes | N/A | Tandem Diabetes Care, Inc. | 28 mi |
| Post Prandial Individual Responses to Different Foods | N/A | Stanford University | 28 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | 28 mi |
| Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) | — | M.D. Anderson Cancer Center | 28 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | 28 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | 28 mi |
| Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | N/A | Stanford University | 28 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | 42 mi |
| Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC) | Phase 4 | Cellution Biologics | 49 mi |